Oramed Pharmaceuticals Inc.

Regulatory Filings • Jan 6, 2022

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burden
hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

1. Name and Address of Reporting Person* Mayer Arie				2. Issuer Name and Ticker or Trading Symbol ORAMED PHARMACEUTICALS INC. [ ORMP ]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner
(Last) 16 MORAN STREET	(First)	(Middle)	01/03/2022	3. Date of Earliest Transaction (Month/Day/Year)					Officer (give title below)	below)	Other (specify
(Street)				4. If Amendment, Date of Original Filed (Month/Day/Year)					Line)	6. Individual or Joint/Group Filing (Check Applicable
KFAR SABA	L3	4428890								X Form filed by One Reporting Person
(City)	(State)	(Zip)								Form filed by More than One Reporting Person
		Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) Date			2. Transaction (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code V		Amount	(A) or		Transaction(s)

				(D)	Price	(Instr. 3 and 4)
Common Stock	01/03/2022	A	6,000	A	(1)	9,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code V		(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$13.89	01/03/2022		A		10,000		(2)	01/03/2032 Common	Stock	10,000	\$0	10,000	D

Explanation of Responses:

1. Represents Restricted Stock Units ("RSUs") that will vest in 4 installments as follows: 1,500 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026. The RSUs convert into the Issuer's Common Stock on a one-for-one basis.

2. The Stock Option will vest in 4 installments as follows: 2,500 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026.

/s/ Arie Mayer 01/05/2022

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

SEC Form 4
------------	--

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burden
hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
(City)	(State)	(Zip)		Form filed by More than One Reporting Person
(Last) (First) (Middle) 6 HADASSA ST. (Street) TEL AVIV, L3 6451306			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person
			3. Date of Earliest Transaction (Month/Day/Year) 01/03/2022	below) below)
1. Name and Address of Reporting Person* Friedman Aviad			2. Issuer Name and Ticker or Trading Symbol ORAMED PHARMACEUTICALS INC. [ ORMP ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title Other (specify
			or Section 30(h) of the Investment Company Act of 1940

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. 8)	4. Securities Acquired (A) or Transaction Disposed Of (D) (Instr. 3, 4 and Code (Instr. 5)		5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
			Code V		Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock	01/03/2022		A		6,000	A	(1)	6,000	D
Common Stock	01/03/2022		(2) G		6,000	D	\$0	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Code (Instr. 8)	Transaction	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code V		(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)
Stock Option (right to buy	\$13.89	01/03/2022		A		10,000		(3)	01/03/2032 Common	Stock	10,000	\$0	10,000	D
Stock Option (right to buy	\$13.89	01/03/2022		(2) G			10,000	(3)	01/03/2032 Common	Stock	10,000	\$0	0	D

Explanation of Responses:

1. Represents Restricted Stock Units ("RSUs") that will vest in 4 installments as follows: 1,500 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026. The RSUs convert into the Issuer's Common Stock on a one-for-one basis.

2. These shares of common stock and stock options were transferred, for no consideration, to a trust with an independent trustee.

3. The Stock Option will vest in 4 installments as follows: 2,500 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026.

	/s/ Aviad Friedman	01/05/2022

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

FORM 4	UNITED STATES SECURITIES AND EXCHANGE COMMISSION
--------	--------------------------------------------------

Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burden
hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

1. Name and Address of Reporting Person* Silberman David		ORMP ]	2. Issuer Name and Ticker or Trading Symbol ORAMED PHARMACEUTICALS INC. [					5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director Officer (give title		10% Owner Other (specify
(Last) 20 MAMILLA AVENUE	(First)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 01/03/2022			X	below)	below) Chief Financial Officer
(Street) JERUSALEM, (City)	L3 (State)	9414904 (Zip)		4. If Amendment, Date of Original Filed (Month/Day/Year)				Line)	6. Individual or Joint/Group Filing (Check Applicable X Form filed by One Reporting Person Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 2. Transaction 1. Title of Security (Instr. 3) Date (Month/Day/Year)				2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
						Code V	(A) or Amount (D)		Price	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock					A		19,000	A	(1)	69,000	D
01/03/2022 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code V		(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$13.89	01/03/2022		A		32,000		(2)	01/03/2032 Common	Stock	32,000	\$0	32,000	D

Explanation of Responses:

1. Represents Restricted Stock Units ("RSUs") that will vest in 4 installments as follows: 4,750 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026. The RSUs convert into the Issuer's Common Stock on a one-for-one basis.

2. The Stock Option will vest in 4 installments as follows: 8,000 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026.

/s/ David Silberman 01/05/2022

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Check this box if no longer subject to Section 16. Form 4 or Form 5

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

	obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940																hours per response:	0.5
1. Name and Address of Reporting Person* Hexter Joshua							2. Issuer Name and Ticker or Trading Symbol ORAMED PHARMACEUTICALS INC. [ ORMP ]									(Check all applicable) Director	5. Relationship of Reporting Person(s) to Issuer 10% Owner
(Last) 9 ALFASI ST.		(First)	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 01/03/2022									Officer (give title Other (specify X below) below) COO & CBO
(Street) JERUSALEM (City)		L3 (State)	92302 (Zip)			4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line) X Person			Form filed by One Reporting Person Form filed by More than One Reporting
															Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)				5. Amount of Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
						Code V Amount							(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)
Common Stock					01/03/2022			A		21,000 A		(1)	124,333			D
			Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned								(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. 8)	5. Number Transaction of Code (Instr. Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) or		Amount	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code V		(A)	(D)	Date Exercisable		Expiration Date	Title		Number of Shares

Explanation of Responses:

Stock Option (right to buy)

1. Represents Restricted Stock Units ("RSUs") that will vest in 4 installments as follows: 5,250 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026. The RSUs convert into the Issuer's Common Stock on a one-for-one basis.

2. The Stock Option will vest in 4 installments as follows: 9,000 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026.

\$13.89 01/03/2022 ^A 36,000 (2) 01/03/2032 Common

/s/ Jushua Hexter 01/05/2022

** Signature of Reporting Person Date

Stock 36,000 \$⁰ 36,000 ^D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burden
hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* RAKIN KEVIN		ORMP ]	2. Issuer Name and Ticker or Trading Symbol ORAMED PHARMACEUTICALS INC. [				X	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title
(Last) 36 CHURCH LANE	(First)	(Middle)	01/03/2022		below) 3. Date of Earliest Transaction (Month/Day/Year)							Other (specify below)
(Street) WESTPORT, (City)	CT (State)	06880 (Zip)		4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person
				Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) Date			2. Transaction (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
						Code V	(A) or Amount (D)		Price	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock 01/03/2022					A		6,000	A	(1)	58,004	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 3. Transaction 3A. Deemed 4. 5. Number 6. Date Exercisable and 7. Title and Amount 8. Price of

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$13.89	01/03/2022		A	10,000		(2)	01/03/2032 Common	Stock	10,000	\$0	10,000	D

Explanation of Responses:

1. Represents Restricted Stock Units ("RSUs") that will vest in 4 installments as follows: 1,500 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026. The RSUs convert into the Issuer's Common Stock on a one-for-one basis.

2. The Stock Option will vest in 4 installments as follows: 2,500 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026.

/s/ Kevin Rakin 01/05/2022

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burden
hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Last)	1. Name and Address of Reporting Person* Sank Leonard (First) (Middle) 3 BLAIR ROAD		2. Issuer Name and Ticker or Trading Symbol ORAMED PHARMACEUTICALS INC. [ ORMP ] 3. Date of Earliest Transaction (Month/Day/Year) 01/03/2022	X	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director Officer (give title below)	10% Owner Other (specify below)
(Street) CAPE TOWN (City)	T3 (State)	8005 (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	Line) X	6. Individual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction 2A. Deemed Date Execution Date, (Month/Day/Year) if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
			Code V		Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock	01/03/2022		A		6,000	A	(1)	6,000	D
Common Stock								138,889	I	By trust(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$13.89	01/03/2022		A	10,000		(3)	01/03/2032 Common	Stock	10,000	\$0	10,000	D

Explanation of Responses:

1. Represents Restricted Stock Units ("RSUs") that will vest in 4 installments as follows: 1,500 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026. The RSUs convert into the Issuer's Common Stock on a one-for-one basis.

2. These shares consist of shares of common stock owned by a company wholly owned by a trust of which the reporting person is a trustee. The reporting person disclaims beneficial ownership of these shares. 3. The Stock Option will vest in 4 installments as follows: 2,500 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026.

/s/ Leonard Sank	01/05/2022

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

FORM 4	UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burden
hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

1. Name and Address of Reporting Person* Rabinowitz Michael			2. Issuer Name and Ticker or Trading Symbol ORAMED PHARMACEUTICALS INC. [	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)
			ORMP ]	Director 10% Owner Officer (give title Other (specify X below) below)
(Last) (First) (Middle) 1185 AVENUE OF THE AMERICAS, THIRD FLOOR			3. Date of Earliest Transaction (Month/Day/Year) 01/03/2022	Chief Commercial Officer
			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line)
(Street) NEW YORK,	NY	10036		X Form filed by One Reporting Person Form filed by More than One Reporting
(City)	(State)	(Zip)		Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
			Code V	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock	01/03/2022		A	19,000	A	(1)	109,468	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$13.89	01/03/2022		A	32,000		(2)	01/03/2032 Common	Stock	32,000	\$0	32,000	D

Explanation of Responses:

1. Represents Restricted Stock Units ("RSUs") that will vest in 4 installments as follows: 4,750 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026. The RSUs convert into the Issuer's Common Stock on a one-for-one basis.

2. The Stock Option will vest in 4 installments as follows: 8,000 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026.

/s/ Michael Rabinowitz 01/05/2022

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

FORM 4	UNITED STATES SECURITIES AND EXCHANGE COMMISSION
--------	--------------------------------------------------

Washington, D.C. 20549

OMB Number:	3235-0287
Estimated average burden
hours per response:	0.5

																			OMB APPROVAL
	Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).	Check this box if no longer subject to										STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934						OMB Number:	Estimated average burden hours per response:	3235-0287 0.5
												or Section 30(h) of the Investment Company Act of 1940
1. Name and Address of Reporting Person* Kidron Miriam					2. Issuer Name and Ticker or Trading Symbol ORAMED PHARMACEUTICALS INC. [ ORMP ]										(Check all applicable) X Director		5. Relationship of Reporting Person(s) to Issuer 10% Owner
(Last)	2 ELZA STREET	(First)	(Middle)				01/03/2022			3. Date of Earliest Transaction (Month/Day/Year)				X below)	Officer (give title	below) Chief Scientific Officer		Other (specify
(Street) JERUSALEM L3 93706						4. If Amendment, Date of Original Filed (Month/Day/Year)										6. Individual or Joint/Group Filing (Check Applicable Line) X			Form filed by One Reporting Person
(City)		(State)	(Zip)										Form filed by More than One Reporting Person
																Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) Date				2. Transaction 2A. Deemed Execution Date, (Month/Day/Year) if any (Month/Day/Year)				3. Transaction Code (Instr. 8)		5)	4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and			5. Amount of Securities Beneficially	Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
										Code V		Amount	(A) or (D)		Price	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)
Common Stock					01/03/2022				A		42,000 A		(1)	183,666			D
			Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned									(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction 3A. Deemed 4. 5. Number Date Execution Date, Transaction of (Month/Day/Year) if any Code (Instr. Derivative (Month/Day/Year) 8) Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Expiration Date (Month/Day/Year)		6. Date Exercisable and 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code V		(A)	(D)		Date Exercisable		Expiration Date	Title		Amount or Number of Shares
Stock

Explanation of Responses:

Option (right to buy)

1. Represents Restricted Stock Units ("RSUs") that will vest in 4 installments as follows: 10,500 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026. The RSUs convert into the Issuer's Common Stock on a one-for-one basis.

2. The Stock Option will vest in 4 installments as follows: 18,000 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026.

\$13.89 01/03/2022 ^A 72,000 (2) 01/03/2032 Common

/s/ Miriam Kidron 01/05/2022

** Signature of Reporting Person Date

Stock 72,000 \$⁰ 72,000 ^D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

SEC Form 4
------------

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burden
hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*	2. Issuer Name and Ticker or Trading Symbol ORAMED PHARMACEUTICALS INC. [	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)
KIDRON NADAV	ORMP ]	X Director 10% Owner
(Last) (First) (Middle)		Officer (give title Other (specify X below) below)
1185 AVENUE OF THE AMERICAS, THIRD FLOOR	3. Date of Earliest Transaction (Month/Day/Year) 01/03/2022	President and CEO
(Street) NEW YORK, NY 10036 (City) (State) (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code V	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)
Common Stock	01/03/2022		A	150,000	A	(1)	936,481	D
Common Stock	01/03/2022		F	48,752(2)	D	\$13.89	887,729	D
Common Stock	01/03/2022		A	63,000	A	(3)	950,729	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Code (Instr. 8)	Transaction	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code V		(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)
Stock Option (right to buy	\$13.89	01/03/2022		A		107,000		(4)	01/03/2032 Common	Stock	107,000	\$0	107,000	D

Explanation of Responses:

1. Represents Common Stock granted by the Issuer that vested upon grant.

2. Payment of tax liability by withholding securities incident to the 150,000 shares of Common Stock granted on January 3, 2022.

3. Represents Restricted Stock Units ("RSUs") that will vest in 4 installments as follows: 15,750 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026. The RSUs convert into the Issuer's Common Stock on a one-for-one basis.

4. The Stock Option will vest in 4 installments as follows: 26,750 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026.

/s/ Nadav Kidron 01/05/2022

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.